Journal
REUMATISMO
Volume 70, Issue 1, Pages 59-66Publisher
PAGEPRESS PUBL
DOI: 10.4081/reumatismo.2018.1062
Keywords
Polymyalgia rheumatica; large vessel vasculitis; glucocorticoids; disease modifying anti-rheumatic drugs; biologics
Categories
Ask authors/readers for more resources
Polymyalgia rheumatica (PCR) is the second most common inflammatory rheumatic disease in the elderly after rheumatoid arthritis. It is clinically characterised by pain and stiffness in the neck, proximal shoulder and hip girdle. Glucocorticoids (GCs) are the cornerstone of PMR treatment, but they are associated with potentially severe side effects. Among GC-sparing agents, methotrexate revealed a modest benefit in clinical trials, and recently, there have been promising reports from tocilizumab. In this review, we summarize the available evidence on the treatment of PMR and the possible role in the future of other agents under investigation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available